Pharvaris NV (FRA:9EN) Valuation Rank


FRA:9EN Pharvaris NV FRA:9EN
28 GF Score
Price €30.70
! 3 Warning Signs
View Full Analysis

What is Pharvaris NV Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Pharvaris NV Valuation Rank Related Terms

FRA:9EN
28GF Score
Pharvaris NV FRA:9EN
Valuation Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Pharvaris NV Business Description

Other Exchanges PHVS:USA
Address Emmy Noetherweg 2, Leiden, NLD, 2333 BK
Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks. The company is also running open-label extension studies in both on-demand (RAPIDe-2) and prophylactic (CHAPTER-4) settings to collect long-term safety and efficacy data in HAE patients.
28GF Score

Get the complete analysis for FRA:9EN

Valuation Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€30.70
Price